FDA-approved1,2,3,4Evidence: Smaller human trialsHormones · Cancer

Lanreotide1

Also called Lanreotide acetate, Somatuline Depot1,2

Key takeaway

Lanreotide is a lab-made analogue of somatostatin, a hormone that suppresses the release of growth hormone and other hormones. It was first approved in the United States as Somatuline Depot in 2007.1,2 It is FDA-approved for three uses: long-term treatment of acromegaly when surgery or radiation has not worked or is not an option, certain advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.1 In the label’s tumor trial of 204 people, disease progression or death occurred in 31.7% of the lanreotide group and 58.3% of the placebo group.1

Lanreotide at a glance

What it isA somatostatin analogue. The label describes lanreotide as an octapeptide, eight amino acids long, that is thought to act like natural somatostatin.1
FDA statusFDA-approved. Drugs@FDA lists Somatuline Depot with an original approval date of August 30, 2007, and later lanreotide applications. The cited label has no boxed warning.1,2,3,4
Human evidenceSmaller randomized, placebo-controlled trials described in the label, in acromegaly, neuroendocrine tumors and carcinoid syndrome.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is lanreotide?

Lanreotide is a lab-made peptide of eight amino acids. The label describes it as an analogue of natural somatostatin.1

Drugs@FDA lists Somatuline Depot, from Ipsen, approved in 2007, and later lanreotide applications approved in 2021 and 2024. The label cited on this page is a generic lanreotide label rather than the Somatuline Depot label.1,2,3,4

How does lanreotide work?

The label states that lanreotide’s mechanism of action is believed to be similar to that of natural somatostatin.1

In acromegaly, the label states that the goal of treatment is to bring growth hormone and IGF-1 levels back to normal.1

What do human studies show?

In a randomized, double-blind, placebo-controlled trial in 204 people with advanced gastroenteropancreatic neuroendocrine tumors, disease progression or death occurred in 31.7% of the lanreotide group and 58.3% of the placebo group, a hazard ratio of 0.47, according to the label.1

In a 16-week trial in 115 people with carcinoid syndrome, the lanreotide group used rescue medicine on 34% of days compared with 49% for placebo. Differences in daily diarrhea and flushing were not statistically significant, according to the label.1

In a one-year acromegaly study of 108 people, 63% of those given lanreotide had a more than 50% drop in growth hormone during the 4-week placebo-controlled phase, compared with none on placebo, according to the label.1

What the evidence base contains

  • Controlled human trial A randomized, double-blind, placebo-controlled trial in 204 people with advanced, well or moderately differentiated gastroenteropancreatic neuroendocrine tumors, with progression-free survival as the main outcome.1
  • Controlled human trial A 16-week randomized, double-blind, placebo-controlled trial in 115 people with neuroendocrine tumors and carcinoid syndrome.1
  • Controlled human trial A one-year acromegaly study in 108 people that began with a 4-week double-blind, placebo-controlled phase.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is lanreotide FDA-approved?

Yes. Drugs@FDA lists Somatuline Depot, application NDA022074, with an original approval date of August 30, 2007, a further lanreotide application (NDA215395) approved on December 17, 2021, and a generic application (ANDA217193) approved on May 21, 2024.2,3,4

The generic lanreotide label cited here (DailyMed SPL version 3, published June 2, 2025) states that it is indicated for long-term treatment of acromegaly when surgery or radiotherapy has not worked or is not an option, for adults with certain unresectable, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and for adults with carcinoid syndrome.1

The label has no boxed warning. It states that lanreotide is contraindicated in people with a history of allergic reactions to it.1

Its warnings cover gallstones and their complications, high or low blood sugar, slowing of the heart rate, thyroid function changes, and fatty stools from poor fat absorption.1

Timeline

  1. FDA approves Somatuline Depot, according to Drugs@FDA.2
  2. FDA approves a further lanreotide application, according to Drugs@FDA.3
  3. FDA approves a generic lanreotide application, according to Drugs@FDA.4
  4. DailyMed publishes the lanreotide label version cited on this page.1

What is still unknown?

Whether lanreotide extends overall survival in neuroendocrine tumors: the label’s tumor trial measured progression-free survival.1

Whether it reduces diarrhea and flushing in carcinoid syndrome: the label reports these differences were not statistically significant.1

How the labels of other lanreotide products differ from the one cited here.1,2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Lanreotide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Lanreotide are the records PeptideScanner has selected and published, not every registration or paper about Lanreotide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Somatuline Depot and other lanreotide products. Smaller randomized, placebo-controlled trials described in the label support its uses, including a tumor trial in which lanreotide lengthened progression-free survival. The cited label has no boxed warning.↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.↗↗↗

What the reviewed sources report

CLARINET found longer progression-free survival, without a demonstrated overall-survival or quality-of-life difference. The acromegaly study reported tumor and hormone changes but did not reject its prespecified primary null hypothesis.↗↗↗

What remains unresolved?

  • How do formulation, indication and prior-treatment differences affect applicability?↗↗↗
  • What do complete trial reports and current labels add about harms and longer follow-up?↗↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Lanreotide acetate injection · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The cited label covers specified acromegaly, gastroenteropancreatic neuroendocrine tumor and carcinoid-syndrome settings. Indications and outcomes differ across those populations. Label: 1 ↗

Which safety limits matter?

Warnings include gallstones and complications, altered glucose control, reduced heart rate, thyroid abnormalities, and fat malabsorption or steatorrhea. These label risks are distinct from event rates in an individual trial. Label: 1, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

Lanreotide acetate injection · SPL version 3 · published 2025-06-02

Label ZIP SHA-256: 549b28079c4ff34c485706fc6353164f8e1903e90a1ec7f10f97482b441b0bfe. Extracted XML SHA-256: c8c3f515d19dbbec43ebb5353991467b8f96123d3e513e3e183fd915087f874b.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Lanreotide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.123

Bottom line from this bounded source set

CLARINET found longer progression-free survival, without a demonstrated overall-survival or quality-of-life difference. The acromegaly study reported tumor and hormone changes but did not reject its prespecified primary null hypothesis.123

Reviewed study record

CLARINET: neuroendocrine tumors

Design

Randomized, double-blind, placebo-controlled trial over 96 weeks.1

Population

204 people with advanced nonfunctioning, somatostatin-receptor-positive grade 1 or 2 neuroendocrine tumors; most had stable disease before enrollment.1

Outcomes reported

The hazard ratio for progression or death was 0.47 (95% CI 0.30–0.73). Overall survival and quality of life did not differ significantly. Treatment-related diarrhea occurred in 26% versus 9%.1

Limitations

The selected tumor grades, receptor status and largely stable baseline disease limit generalization. Progression-free survival is distinct from longer overall survival.1

Reviewed study record

CLARINET open-label extension

Design

Eligible original-trial participants entered an extension in which everyone received lanreotide.2

Population

89 participants entered: 42 previously assigned lanreotide and 47 previously assigned placebo.2

Outcomes reported

The continuous-treatment group had a reported median progression-free survival of 38.5 months. Adverse-event incidence was lower during extension than during the core study.2

Limitations

Selective extension enrollment, crossover and absence of a concurrent placebo group prevent an independent randomized long-term comparison.2

Reviewed study record

PRIMARYS: acromegaly

Design

48-week open-label, single-arm study with centrally assessed tumor volume.3

Population

90 treatment-naïve people with acromegaly and growth-hormone-secreting macroadenomas entered; 64 completed.3

Outcomes reported

The primary analysis found at least 20% tumor-volume reduction in 62.9% of 89 participants, but the prespecified null hypothesis was not rejected. Hormonal and symptom measures also improved.3

Limitations

No control group, attrition and differences between primary and sensitivity analyses limit causal interpretation. No gastrointestinal-intolerance withdrawals does not mean no adverse events.3

Reviewed source set

  1. PubMed · 25014687Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗PubMed PMID 25014687 · EFetch XML reviewed 2026-09-15 · payload SHA-256 ba560cbc89f579f1c9993801784e3b4e4720505fa3a71815cb4d17396ad5a315
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1316158. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 33052555Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. ↗PubMed PMID 33052555 · EFetch XML reviewed 2026-09-15 · payload SHA-256 965ff6216bbf51d5c511964f6dc349e1756d0980802f50665ca54b21e9fd4f86
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s12020-020-02475-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 24423301Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. ↗PubMed PMID 24423301 · EFetch XML reviewed 2026-09-15 · payload SHA-256 b36766502f349560e081866b918e66b57fcd9b2022520b5b4dffeecec32622a4
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2013-3318. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The tumor study measured progression-free survival

FDA’s December 2014 review describes a 204-participant, randomized, double-blind placebo-controlled trial in unresectable or metastatic, well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors. The primary endpoint combined radiological progression or death. FDA PDF pp. 32, 36 ↗

More findings, study links and document coverage

Delayed progression did not establish longer survival

FDA found longer progression-free survival with lanreotide. Overall-survival data were immature with no apparent difference between groups at that assessment, so these outcomes should not be treated as interchangeable. FDA PDF pp. 32 ↗

Most participants had stable disease before entry

Nearly all participants had stable disease before randomization. That population limits extrapolation of the result to every rapidly progressing tumor or tumor subtype. FDA PDF pp. 32 ↗

The safety account is indication-specific

The reviewed tumor study reported glucose abnormalities, bradycardia and gallbladder findings. Its exposure and population differ from the earlier acromegaly program; this supplement is not a complete review of every lanreotide use. FDA PDF pp. 40 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Somatuline Depot: FDA selected application review ↗

    Selected sections reviewed · fda-lanreotide-review-2014 · Document/feed date: 2014-12-16

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Somatuline Depot · NDA 022074 · Document dated 2014-12-16. Identity checked on PDF pp. 31.

    Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.

    Retrieved 2026-09-19. Read PDF pages: 31, 32, 36, 40 of 199. SHA-256: 1130ab9cde9c9010cc5f49111f51bac7d096d273aef7696d05817de03fbd0a93.

Remaining work

  • Review the original acromegaly and later carcinoid-syndrome assessments separately.
  • Appraise CLARINET extension and survival follow-up, preserving crossover and enrollment limitations.

Open versioned document coverage and study pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Identity/name search without publication-type filtering; primary human reports, extensions, combinations and other reports require separate eligibility decisions. Known selected reports were recovered.

1259 retrieved · 3 included · 0 excluded · 1256 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"lanreotide"[Title/Abstract] OR "Somatuline"[Title/Abstract]

  • Full-text appraisal and screening of unassessed records remain open.
  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.

Showing 25 of 1259 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 33052555 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00353496.
  2. PubMed 25014687 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00353496.
  3. PubMed 24423301 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00690898.
  4. PubMed 42721062 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  5. PubMed 42642161 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  6. PubMed 42703492 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  7. PubMed 42675372 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  8. PubMed 42723843 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  9. PubMed 42729617 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  10. PubMed 42621460 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  11. PubMed 42206253 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  12. PubMed 42053775 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  13. PubMed 42597314 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  14. PubMed 42476150 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  15. PubMed 42442850 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  16. PubMed 42319153 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  17. PubMed 41308086 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  18. PubMed 42365543 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  19. PubMed 42359578 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  20. PubMed 42320793 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  21. PubMed 42030411 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  22. PubMed 41965092 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  23. PubMed 42395255 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  24. PubMed 41964795 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  25. PubMed 41948193 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

3 retrieved · 3 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"LANREOTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:17.646636+00:00 · HTTP 200 · SHA-256 6d38b151d3afa503018c40627791da17e043f4509fc8931e9362836ac2c4224f.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 3 of 3 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA022074 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LANREOTIDE ACETATE.
  2. FDA ANDA217193 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LANREOTIDE ACETATE.
  3. FDA NDA215395 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LANREOTIDE ACETATE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Lanreotide", "Lanreotide acetate"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

    10 retrieved · 0 included · 0 excluded · 10 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Lanreotide", "Lanreotide acetate"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 10 of 10 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. EMA 25634 — not screened: Title-name match awaiting identity and document review. Lanreotide: List of nationally authorised medicinal products - PSUSA/00001826/201705
    2. EMA 36352 — not screened: Title-name match awaiting identity and document review. EU/3/15/1514: Public summary of opinion on orphan designation: Lanreotide acetate for the treatment of autosomal dominant polycystic kidney disease
    3. EMA 51091 — not screened: Title-name match awaiting identity and document review. Lanreotide: List of nationally authorised medicinal products - PSUSA/00001826/202005
    4. EMA 53723 — not screened: Title-name match awaiting identity and document review. Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202105
    5. EMA 56988 — not screened: Title-name match awaiting identity and document review. Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg productspecific bioequivalence guidance
    6. EMA 56989 — not screened: Title-name match awaiting identity and document review. Overview of comments on 'Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance'
    7. EMA 57366 — not screened: Title-name match awaiting identity and document review. Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202205
    8. EMA 54970 — not screened: Title-name match awaiting identity and document review. Draft lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product specific bioequivalence guidance
    9. EMA 62726 — not screened: Title-name match awaiting identity and document review. Lanreotide : List of nationally authorised medicinal products - PSUSA/00001826/202305
    10. EMA 6785 — not screened: Title-name match awaiting identity and document review. P/0302/2013: EMA decision of of 29 November 2013 on the granting of a product-specific waiver for lanreotide (acetate) (Somatuline LA and associated names) (EMEA-001503-PIP01-13)

    EMA search

    Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

    1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Lanreotide", "Lanreotide acetate"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. EMA EU/3/15/1514 — include: EMA orphan feed identifies Lanreotide acetate; designation status: Positive. Orphan designation is not marketing authorization.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    124 retrieved · 0 included · 0 excluded · 124 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Lanreotide" OR "Lanreotide acetate"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:16.840936+00:00 · HTTP 200 · SHA-256 e2f792259e06d2fa9bb9c1111e1d2195bc27bbf34083a51a523bc91eedb3c135.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:18.098734+00:00 · HTTP 200 · SHA-256 6d6198aaffa3829940b1e80a49c9b01d30f704edc837a7f8ec4d1ac1b96b9505.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 124 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT02020499 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT00234572 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT00543179 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT00216372 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT05048901 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT01137682 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT00729313 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT03289741 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT00353496 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT02127437 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT00630695 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT07534371 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT00774930 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT03562091 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT03792555 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT07179926 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT02685709 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT01538966 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT04198402 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT02788578 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT03112694 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT05922579 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT03083210 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT00747500 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT02288377 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Lanreotide?

    FDA-approved as Somatuline Depot and other lanreotide products. Smaller randomized, placebo-controlled trials described in the label support its uses, including a tumor trial in which lanreotide lengthened progression-free survival. The cited label has no boxed warning.↗↗↗↗

    The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

    Evidence present

    What records are connected here?

    Evidence lanes
    4
    Source years
    15
    Drugs@FDA applications
    4

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Collection changes

    What did PeptideScanner add most recently?

    1. Regulatory · added November 15, 2026

      Drugs@FDA application ANDA218217↗Source date September 18, 2026
    2. Literature metadata · added November 14, 2026

      A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study.↗Source date November 13, 2026
    3. Literature metadata · added November 14, 2026

      Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.↗Source date September 30, 2026

    Coverage gaps

    What remains unknown or unsupported?

    All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Lanreotide?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    74Selected dated records
    75Connected citations
    15Populated source years2007–2026
    4/4Record lanes present

    Registered human studies

    Trial composition

    2 of 13 selected trial records include at least one phase value; 2 of 13 include a status value in the retained structured contract.

    108 public history versions connect to 12 of these trial records across 20 submitted years. Open the record-history collection →

    PhasesPhase 3 2
    Status at observationCompleted 2

    A phase value is unavailable here for 11 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 11 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    25 of 49 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesJournal Article 20Case Reports 6Clinical Trial 6Research Support, Non-U.S. Gov't 6Letter 5Multicenter Study 5Clinical Trial, Phase II 2Clinical Trial, Phase III 1Comment 1Comparative Study 1Randomized Controlled Trial 1Review 1

    Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    4
    FDA Federal Register documents
    2
    DailyMed SPL versions
    3
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    74

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts
    Source records by collection · 74 dated records

    Research hub

    Explore the Lanreotide evidence record

    Open all 74 records →
    74Dated records
    4Evidence types
    74Cited public sources
    15Source years

    Change ledger

    Recently changed for Lanreotide

    Open all 76 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Profile status changed

    Lanreotide profile

    We added a plain-language reader guide with cited answers, re-checked the generic lanreotide label, and added Drugs@FDA approval records for lanreotide products.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile
    Record added

    Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.

    PubMed lists PMID 42721062 in Archives of endocrinology and metabolism as Case Reports, Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

    PeptideScanner change date
    November 14, 2026
    Cited source date
    September 21, 2026
    Evidence lane
    Literature metadata

    Official-source collections

    Source records for Lanreotide

    Open the full research atlas →
    PubMed49

    25 with attributed title, venue, publication-date, and type metadata.

    1. A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study.ESMO open · 2026 11 03
    2. Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.Cancer medicine · 2026 Oct
    3. Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.Archives of endocrinology and metabolism · 2026 09 10
    Explore all selected literature →
    ClinicalTrials.gov13

    108 public history versions across these dated registry records; status labels apply only to each cited observation.

    1. NCT05048901Registry update April 9, 2026 · current at observation
    2. NCT02127437Registry update April 8, 2026 · completed at observation
    3. NCT06807437Registry update March 31, 2026 · current at observation
    Explore all selected trial records →Explore all public record history →
    Drugs@FDA4

    Original-submission application metadata connected by exact reviewed active-ingredient names.

    1. ANDA218217Full FDA chronology · original submission status AP 2026-09-18
    2. ANDA217193Full FDA chronology · original submission status AP 2024-05-21
    3. NDA215395Full FDA chronology · original submission status AP 2021-12-17
    4. NDA022074Full FDA chronology · original submission status AP 2007-08-30
    Explore all selected FDA applications →Explore 24 dated submissions and 39 documents for Lanreotide →
    FDA enforcement reports3

    Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

    1. D-0422-2026Class II · report date 2026-04-15
    2. D-0423-2026Class II · report date 2026-04-15
    3. D-0290-2026Class II · report date 2026-01-21
    Explore all exact FDA enforcement reports →

    Evidence types

    Coverage by source year

    Selected records span August 30, 2007 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Organizations and trial records named in cited sources

    Organizations named in cited records

    • U.S. National Library of Medicine1
    • U.S. Food and Drug Administration2
    Dated updates connected to this profile · 74

    Updates connected to this profile

    Open the full cross-source timeline →
    1. Literature metadata

      A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study.↗

      PubMed lists PMID 42976416 in ESMO open as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    2. Literature metadata

      Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.↗

      PubMed lists PMID 42791653 in Cancer medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    3. Literature metadata

      Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy.↗

      PubMed lists PMID 42721062 in Archives of endocrinology and metabolism as Case Reports, Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    4. Regulatory

      Drugs@FDA application ANDA218217↗

      The official Drugs@FDA dataset lists original submission 1 for ANDA 218217 with status AP dated 2026-09-18, and names lanreotide acetate among the application record's active ingredients.↗

    5. Literature metadata

      PubMed record PMID 41880072↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41880072 at 2026-07-30T16:14:14.928Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-03-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    6. Literature metadata

      PubMed record PMID 39933708↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 39933708 at 2026-07-30T16:14:10.854Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2025-02-11. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    7. Literature metadata

      PubMed record PMID 38071418↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38071418 at 2026-07-30T16:20:36.586Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-12-10. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    8. Literature metadata

      β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide.↗

      PubMed lists PMID 39491674 in Journal of pharmaceutical sciences as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-02 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    9. Literature metadata

      Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.↗

      PubMed lists PMID 38206830 in The oncologist as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2024-05-03 (day precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

    10. Safety

      FDA enforcement report D-0422-2026↗

      FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.↗

    11. Safety

      FDA enforcement report D-0423-2026↗

      FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.↗

    12. Clinical trials

      ClinicalTrials.gov record NCT05048901↗

      PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.↗

    Citations

    Sources

    Coverage and sources →

    Numbered markers in the text point here. Each link opens the original public record.

    1. 1
      Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗

      DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

    2. 2
      Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    3. 3
      Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    4. 4
      Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026